• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ICOS/ICOS-L 免疫复合物的结构特征揭示了治疗性抗体的高度分子模拟性。

Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.

机构信息

Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, M5G 0A4, Canada.

Biofisika Institute (CSIC, UPV/EHU) and Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), P.O. Box 644, 48080, Bilbao, Spain.

出版信息

Nat Commun. 2020 Oct 8;11(1):5066. doi: 10.1038/s41467-020-18828-4.

DOI:10.1038/s41467-020-18828-4
PMID:33033255
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7545189/
Abstract

The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L). Dysregulation of this pathway has been implicated in autoimmune diseases and cancer, and is currently under clinical investigation as an immune checkpoint blockade. Here, we describe the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution. A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members. Furthermore, our structure and binding data reveal that the ICOS N110 N-linked glycan participates in ICOS-L binding. In addition, we report crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy. Strikingly, antibody paratopes closely mimic receptor-ligand binding core interactions, in addition to contacting peripheral residues to confer high binding affinities. Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.

摘要

诱导共刺激分子(ICOS)是 CD28/B7 超家族的成员,在与配体(ICOS-L)结合后,向激活的 T 细胞传递正向共刺激信号。该途径的失调与自身免疫性疾病和癌症有关,目前正在作为免疫检查点阻断剂进行临床研究。在这里,我们在 3.3Å 分辨率下描述了 ICOS/ICOS-L 免疫复合物的分子相互作用。ICOS 中的中央 FDPPPF 基序和 CC'环内的残基负责与 ICOS-L 的特异性相互作用,与其他家族成员相比,具有独特的受体结合取向。此外,我们的结构和结合数据表明,ICOS 的 N110 N 连接聚糖参与 ICOS-L 结合。此外,我们还报告了处于临床评估阶段的免疫疗法中用于治疗的单克隆抗体与 ICOS 和 ICOS-L 复合物的晶体结构。引人注目的是,抗体的抗原结合部位模拟了受体-配体结合的核心相互作用,除了与外围残基结合以赋予高结合亲和力之外。我们的研究结果揭示了人类适应性免疫中至关重要的免疫复合物的关键分子相互作用,对正在开发的针对免疫检查点受体的治疗干预措施具有直接影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d4/7545189/0daabd2dfac2/41467_2020_18828_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d4/7545189/314e266470f4/41467_2020_18828_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d4/7545189/ed18c584b132/41467_2020_18828_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d4/7545189/f8df2fd3183b/41467_2020_18828_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d4/7545189/3d6c6e7146a8/41467_2020_18828_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d4/7545189/b89478ecd429/41467_2020_18828_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d4/7545189/0daabd2dfac2/41467_2020_18828_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d4/7545189/314e266470f4/41467_2020_18828_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d4/7545189/ed18c584b132/41467_2020_18828_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d4/7545189/f8df2fd3183b/41467_2020_18828_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d4/7545189/3d6c6e7146a8/41467_2020_18828_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d4/7545189/b89478ecd429/41467_2020_18828_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31d4/7545189/0daabd2dfac2/41467_2020_18828_Fig6_HTML.jpg

相似文献

1
Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.ICOS/ICOS-L 免疫复合物的结构特征揭示了治疗性抗体的高度分子模拟性。
Nat Commun. 2020 Oct 8;11(1):5066. doi: 10.1038/s41467-020-18828-4.
2
Structural basis of inducible costimulator ligand costimulatory function: determination of the cell surface oligomeric state and functional mapping of the receptor binding site of the protein.诱导性共刺激分子配体共刺激功能的结构基础:细胞表面寡聚状态的确定及该蛋白受体结合位点的功能图谱分析
J Immunol. 2006 Sep 15;177(6):3920-9. doi: 10.4049/jimmunol.177.6.3920.
3
CTLA4-Ig-Based Bifunctional Costimulation Inhibitor Blocks CD28 and ICOS Signaling to Prevent T Cell Priming and Effector Function.基于 CTLA4-Ig 的双功能共刺激抑制剂阻断 CD28 和 ICOS 信号传导,以防止 T 细胞启动和效应功能。
J Immunol. 2021 Mar 1;206(5):1102-1113. doi: 10.4049/jimmunol.2001100. Epub 2021 Jan 25.
4
Ligand binding sites of inducible costimulator and high avidity mutants with improved function.可诱导共刺激分子的配体结合位点及功能改进的高亲和力突变体
J Exp Med. 2002 Apr 15;195(8):1033-41. doi: 10.1084/jem.20011607.
5
A signaling-enhanced chimeric receptor to activate the ICOS pathway in T cells.一种用于激活T细胞中ICOS途径的信号增强嵌合受体。
J Immunol Methods. 2015 Sep;424:14-9. doi: 10.1016/j.jim.2015.04.015. Epub 2015 May 5.
6
ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy.诱导共刺激分子配体(ICOS-L)作为癌症免疫治疗的潜在治疗靶点。
Curr Protein Pept Sci. 2018;19(11):1107-1113. doi: 10.2174/1389203719666180608093913.
7
Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).靶向同种异体反应性T细胞上表达的诱导性共刺激分子(ICOS)可下调移植物抗宿主病(GVHD)并促进异基因骨髓(BM)的植入。
Blood. 2005 Apr 15;105(8):3372-80. doi: 10.1182/blood-2004-10-3869. Epub 2004 Dec 23.
8
The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.癌症免疫治疗中靶向ICOS-ICOS配体共刺激通路的基本原理。
ESMO Open. 2020 Jan;5(1). doi: 10.1136/esmoopen-2019-000544.
9
Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL.CD28/B7、ICOS/GL50和ICOS/GL50B共刺激途径在小鼠肿瘤模型中的体内疗效相当:IFNγ依赖性增强CTL启动、效应功能和肿瘤特异性记忆CTL。
Cell Immunol. 2003 Sep;225(1):53-63. doi: 10.1016/j.cellimm.2003.09.002.
10
Inducible Co-Stimulator (ICOS) in transplantation: A review.诱导共刺激分子(ICOS)在移植中的作用:综述。
Transplant Rev (Orlando). 2022 Dec;36(4):100713. doi: 10.1016/j.trre.2022.100713. Epub 2022 Jul 9.

引用本文的文献

1
Primary Cutaneous CD4+ Small/Medium-Sized T-Cell Lymphoproliferative Disorder: A Retrospective Cohort Study of 40 Adult Patients.原发性皮肤CD4+小/中型T细胞淋巴增殖性疾病:40例成年患者的回顾性队列研究
Am J Dermatopathol. 2025 Jul 31;47(9):657-673. doi: 10.1097/DAD.0000000000002981.
2
Directed evolution and modular integration of a high-affinity ICOS-L variant for potent T cell-mediated tumor elimination.用于高效T细胞介导的肿瘤消除的高亲和力ICOS-L变体的定向进化和模块化整合。
J Biol Eng. 2025 Jul 11;19(1):63. doi: 10.1186/s13036-025-00536-6.
3
CD28 and ICOS in immune regulation: Structural insights and therapeutic targeting.

本文引用的文献

1
Inducible T-cell co-stimulator: Signaling mechanisms in T follicular helper cells and beyond.可诱导共刺激分子:滤泡辅助性 T 细胞中的信号机制及其他作用。
Immunol Rev. 2019 Sep;291(1):91-103. doi: 10.1111/imr.12771.
2
Nonimmune cell-derived ICOS ligand functions as a renoprotective αvβ3 integrin-selective antagonist.非免疫细胞衍生的 ICOS 配体作为一种肾保护的 αvβ3 整联蛋白选择性拮抗剂发挥作用。
J Clin Invest. 2019 Apr 1;129(4):1713-1726. doi: 10.1172/JCI123386. Epub 2019 Mar 18.
3
Cemiplimab: First Global Approval.西尼莫单抗:全球首次获批。
CD28和ICOS在免疫调节中的作用:结构见解与治疗靶点
Bioorg Med Chem Lett. 2025 Jun 15;127:130310. doi: 10.1016/j.bmcl.2025.130310.
4
Global research prospects and trends in TFH cells and tumors: a bibliometric analysis.滤泡辅助性T细胞与肿瘤的全球研究前景及趋势:一项文献计量分析
Front Oncol. 2025 Feb 14;15:1443890. doi: 10.3389/fonc.2025.1443890. eCollection 2025.
5
From Virtual Screens to Cellular Target Engagement: New Small Molecule Ligands for the Immune Checkpoint LAG-3.从虚拟筛选到细胞靶点结合:免疫检查点LAG-3的新型小分子配体
ACS Med Chem Lett. 2024 Oct 15;15(11):1884-1890. doi: 10.1021/acsmedchemlett.4c00350. eCollection 2024 Nov 14.
6
Ig or Not Ig? That Is the Question: The Nucleating Supersecondary Structure of the Ig-Fold and the Extended Ig Universe.Ig 还是非 Ig?这是个问题:Ig 折叠的成核超二级结构和扩展的 Ig 宇宙。
Methods Mol Biol. 2025;2870:371-396. doi: 10.1007/978-1-0716-4213-9_19.
7
Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC.在头颈部鳞状细胞癌中,联合使用ATM或ATR抑制剂与低分割放疗会在转录和蛋白质水平上导致不同的免疫表型。
Front Oncol. 2024 Oct 1;14:1460150. doi: 10.3389/fonc.2024.1460150. eCollection 2024.
8
Triscysteine disulfide-directing motifs enabling design and discovery of multicyclic peptide binders.三半胱氨酸二硫键导向基序,可用于设计和发现多环肽结合物。
Nat Commun. 2024 Sep 6;15(1):7799. doi: 10.1038/s41467-024-51723-w.
9
Uncovering the Expression Pattern of the Costimulatory Receptors ICOS, 4-1BB, and OX-40 in Exhausted Peripheral and Tumor-Infiltrating Natural Killer Cells from Patients with Cervical Cancer.揭示宫颈癌患者外周衰竭和肿瘤浸润自然杀伤细胞中共刺激受体 ICOS、4-1BB 和 OX-40 的表达模式。
Int J Mol Sci. 2024 Aug 12;25(16):8775. doi: 10.3390/ijms25168775.
10
Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles.通过大规模RNA谱的分解来阐明免疫相关基因转录程序。
iScience. 2024 May 23;27(6):110096. doi: 10.1016/j.isci.2024.110096. eCollection 2024 Jun 21.
Drugs. 2018 Nov;78(17):1841-1846. doi: 10.1007/s40265-018-1012-5.
4
Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.简要报告:一项评估 AMG 557 治疗系统性红斑狼疮和活动性狼疮关节炎患者的随机、双盲、平行分组、安慰剂对照、多剂量研究。
Arthritis Rheumatol. 2018 Jul;70(7):1071-1076. doi: 10.1002/art.40479. Epub 2018 May 25.
5
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.靶向糖基化 PD-L1 消除三阴性乳腺癌细胞
Cancer Cell. 2018 Feb 12;33(2):187-201.e10. doi: 10.1016/j.ccell.2018.01.009.
6
Structural Basis of Enhanced Crystallizability Induced by a Molecular Chaperone for Antibody Antigen-Binding Fragments.分子伴侣增强抗体抗原结合片段可结晶性的结构基础。
J Mol Biol. 2018 Feb 2;430(3):322-336. doi: 10.1016/j.jmb.2017.12.010. Epub 2017 Dec 22.
7
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.抗 PD-L1 抗体阿特珠单抗和度伐鲁单抗通过 PD-1/PD-L1 阻断的分子机制。
Sci Rep. 2017 Jul 17;7(1):5532. doi: 10.1038/s41598-017-06002-8.
8
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.重组溶瘤病毒在肿瘤内调节诱导共刺激分子 ICOS 促进全身抗肿瘤免疫。
Nat Commun. 2017 Feb 13;8:14340. doi: 10.1038/ncomms14340.
9
Inducible costimulator (ICOS) potentiates TCR-induced calcium flux by augmenting PLCγ1 activation and actin remodeling.诱导性共刺激分子(ICOS)通过增强磷脂酶Cγ1(PLCγ1)的激活和肌动蛋白重塑来增强T细胞受体(TCR)诱导的钙流。
Mol Immunol. 2016 Nov;79:38-46. doi: 10.1016/j.molimm.2016.09.022. Epub 2016 Sep 29.
10
A TRAF-like motif of the inducible costimulator ICOS controls development of germinal center TFH cells via the kinase TBK1.诱导性共刺激分子ICOS的一个类TRAF基序通过激酶TBK1控制生发中心TFH细胞的发育。
Nat Immunol. 2016 Jul;17(7):825-33. doi: 10.1038/ni.3463. Epub 2016 May 2.